Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer

OBJECTIVE: S-1 and modified FOLFIRINOX (mFFX) were often used as the second-line chemotherapies after failure of gemcitabine plus nab-paclitaxel (GnP) in unresectable pancreatic cancer (UPC) until nanoliposomal irinotecan plus 5-fluorouracil/leucovorin therapy was approved as an alternative in Japan...

Descripción completa

Detalles Bibliográficos
Autores principales: Hino, Kaori, Nishina, Tomohiro, Numata, Yuuki, Asagi, Akinori, Inoue, Tomonori, Yoshimatsu, Megumi, Sakaguchi, Chihiro, Nakasya, Akio, Nishide, Norifumi, Kajiwara, Takeshi, Terao, Takashi, Nadano, Seijin, Marui, Kaori, Okujima, Yusuke, Kokubu, Masahito, Imamura, Yoshiki, Kanemitsu, Kozue, Koizumi, Mitsuhito, Kumagi, Teru, Hiasa, Yoichi, Hyodo, Ichinosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424096/
https://www.ncbi.nlm.nih.gov/pubmed/35908959
http://dx.doi.org/10.2169/internalmedicine.8736-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424096/
https://www.ncbi.nlm.nih.gov/pubmed/35908959
http://dx.doi.org/10.2169/internalmedicine.8736-21

Ejemplares similares